Kodiak Sciences
Kodiak Sciences Inc is an American clinical-stage biopharmaceutical company developing retinal therapeutics to treat high-prevalence ophthalmic diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate platform to engineer long-acting biotherapeutics, advancing lead candidates including tarcocimab tedromer for diabetic retinopathy and retinal vein occlusion. Main revenue drivers currently comprise investment capital financing, research partnership grants, and development licensing agreements as Phase III clinical trials advance. Kodiak Sciences targets retina specialists, clinical research centers, biopharmaceutical partners, and patients with vascular retinal diseases across North America and Europe. The company holds an innovative position in long-acting biopolymer conjugate therapeutics for ophthalmology. Headquartered in Palo Alto, California, Kodiak Sciences Inc is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Kodiak Sciences.
- Legal name
- Kodiak Sciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Kodiak Sciences
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.4 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)